VERAXA Biotech (NASDAQ: VRXA) announced an expansion of its intellectual property portfolio, filing new patent applications during the first half of 2026 covering its next-generation BiTAC-TCE and BiTAC-ADC technology platforms and related therapeutic programs. The company said previously granted patents protecting supporting technologies have also cleared the opposition period, bringing its portfolio to more than 50 granted owned or exclusively licensed patents across 14 countries and 26 patent families. Pending approval of the latest filings, VERAXA expects its core technologies to be protected through at least 2047.
The company said its BiTAC platform is designed to improve the selectivity and safety of cancer therapies by activating treatments only when multiple tumor-associated targets are present. VERAXA also highlighted proprietary click chemistry, conjugation, linker and payload technologies intended to enhance the safety, efficacy and manufacturability of its antibody-drug conjugate and T-cell engager pipelines, reinforcing its long-term strategy to develop next-generation oncology therapeutics.
At a glance
- Company
- VERAXA Biotech
- Ticker
- NASDAQ: VRXA
- Announcement
- Expansion
Key figures
- Granted owned or exclusively licensed patents
- more than 50
- Countries covered
- 14
- Patent families
- 26
- Expected core technology protection, pending approval
- through at least 2047
Products and programs
To view the full press release, visit https://ibn.fm/BqhFS
About VERAXA Biotech AG
At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
In brief
VERAXA Biotech says it filed patent applications in the first half of 2026 for its BiTAC-TCE and BiTAC-ADC platforms and related therapeutic programs. It also reports that patents covering supporting technologies have passed their opposition period. The company describes its portfolio as comprising more than 50 granted patents that it owns or licenses exclusively, spanning 14 countries and 26 patent families. If the new applications are approved, VERAXA expects its core technologies to have protection through at least 2047. The company says its BiTAC approach is intended to activate cancer treatments when multiple tumor-associated targets are present. It also cites click chemistry, conjugation, linker and payload technologies intended to support its antibody-drug conjugate and T-cell engager programs.
Key takeaways
- VERAXA filed patent applications covering its BiTAC-TCE and BiTAC-ADC platforms and related programs.
- The company says its portfolio includes more than 50 granted owned or exclusively licensed patents.
- The portfolio spans 14 countries and 26 patent families, according to VERAXA.
- The company expects core technology protection through at least 2047 if the latest filings are approved.
SEC filings
Earlier from VERAXA Biotech AG
- VERAXA Biotech (NASDAQ: VRXA) Shareholders Approve Corporate Governance, Financing Measures
- VERAXA Biotech (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration
- VERAXA Biotech (NASDAQ: VRXA) Advances BiTAC(R)-TCE Development with Positive Regulatory Feedback from Germany
- VERAXA Biotech (NASDAQ: VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform
- VERAXA Biotech (NASDAQ: VRXA) Partners With Ardigen to Advance AI-Driven Cancer Drug Development
